Anakinra authorized to treat severe coronavirus disease 2019; Sepsis breakthrough or time to reflect?
Description
INTRODUCTION: The European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) announced conditions for using recombinant human interleukin-1 receptor antagonist (rhIL-1ra) to treat hospitalized patients with Coronavirus
